Selection of medicines in packaging

NICE recommends chemotherapy-free treatment option

Patients suffering with untreated chronic lymphocytic leukaemia (CCL) may soon be offered a new treatment option after NICE recommended a new chemotherapy-free treatment option for use as part of new final draft guidance.

The newly-recommended drug combination – a mixture of a daily orally-administer drug and an intravenously-administered secondary drug – is set to benefit more than 1,000 people each year.

Following the new guidance, the fixed 12-month chemotherapy-free treatment will be offered to people with CLL who have not received any prior treatments.

It will be offered as a first-line treatment to people with CLL with certain genetic abnormalities. For those without, it will be offered to people with untreated CLL for whom other existing drug combinations are unsuitable.

Affecting white blood cells, CLL is the most common of the chronic leukaemias and accounts for around 30% of all leukaemia cases affecting adults.

In England in 2017, there were 3,157 new cases of CLL recorded.

The new drug combination, referred to as venetoclax plus obinutuzumab, has been recommended to be included by NICE as a new treatment option via the Cancer Drugs Fund, including for people with untreated CLL without a genetic abnormality and for whom other options are suitable. This is to allow for greater evidence to be gathered on its cost effectiveness in this group.

Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation at NICE, said: “Today’s announcement is good news for many people with chronic lymphocytic leukaemia.

“We are pleased the company engaged with NICE and NHSE/I to agree a commercial arrangement that will ensure access to this valuable new treatment option.”

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all